Search the record

Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims

Health if she will provide an update on the process to allow for the reimbursement of Skyclarys, the only approved treatment for Friedreich’s Ataxia (FA); the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations

Minister for Health if she will consider making the drug Omaveloxolone available to the approximately 200 people in Ireland currently living with Friedreich's Ataxia, given the life-changing impact this drug can have; if she will reconsider her position that the drug is not ‘economically viable

Deputy Denise Mitchell asked the Minister for Health if consideration will be given to making the medication Skyclarys (omaveloxolone) available to Irish Friedreich’s Ataxia patients under the current drugs reimbursement process; if she recognises the clinical necessity of this request as this drug is the only proven

Deputy Barry Heneghan asked the Minister for Health when Skyclarys (omaveloxolone), the first approved treatment for Friedreich’s ataxia, will be made available to patients in Ireland through reimbursement; if she will prioritise the assessment and reimbursement process given the urgent clinical need for the approximately 200 people

prioritising the reimbursement process for omaveloxolone to ensure that it is made available to the approximately 200 people in Ireland living with Friedreich’s ataxia; if she recognises the clinical necessity of this treatment for a community that currently has no other therapeutic options; and if she will

Deputy John McGuinness asked the Minister for Health if the drug sky clarys (omaveloxolone) used for the treatment of Friedreichs ataxia will be made available under licence in Ireland; if she will outline the process to licence the drug; the timeline involved; and if she will make

Daly asked the Minister for Health if there are plans to introduce skyclarys (omaveloxolone) into the Irish market for the treatment of Friedreich's ataxia in adults and adolescents; which is approved in America, Canada, UK, some European countries but not Ireland to date; and if she will

supplied), aged 51-years-old and suffering with MS, who is currently awaiting assessment by a neurologist as to whether they have Friedreich's ataxia; and if she will make a statement on the matter. [23667/25